Investment Rating - The report does not explicitly state an investment rating for the hepatitis screening industry Core Insights - The hepatitis early screening market in China is projected to grow from 311.65 billion RMB in 2018 to 781.42 billion RMB by 2028, reflecting a compound annual growth rate (CAGR) of approximately 6.19% [5] - The estimated number of high-risk screening populations is expected to decline from approximately 11.91 million in 2018 to about 10.46 million by 2028 [21] - The hepatitis B infection rate among Chinese residents is projected to decrease from 7.95% in 2018 to 6.45% by 2028, indicating a declining trend in infection rates [14] - The hepatitis C infection rate is expected to stabilize at around 0.9% from 2024 to 2028 after a steady increase from 0.56% in 2018 [18] Summary by Sections Hepatitis Early Screening Market Size - The hepatitis early screening market size is calculated based on the formula L*M, where L represents the number of screenings and M represents the coverage rate [5] - The market size in RMB for the years 2018 to 2028 shows a consistent growth trend, with a peak of 781.42 billion RMB in 2028 [5] Population and Infection Rates - The total population of China is projected to grow slowly, from 140.01 million in 2018 to 142.35 million by 2028 [10] - The hepatitis B infection rate is expected to decline steadily, while the hepatitis C infection rate is projected to stabilize [14][18] High-Risk Screening Population - The number of high-risk screening populations is calculated based on the total population and infection rates, showing a decrease over the years [21] - The screening frequency for high-risk individuals is set at once per year, with a consistent average cost of 200 RMB per screening [26][28] Ordinary Screening Population - The ordinary screening population is estimated to decrease slightly from 100.07 million in 2018 to 95.82 million by 2030 [35] - The average cost for ordinary screenings is maintained at 80 RMB per person [41] Recommended Screening Scale - The recommended scale for high-risk screening is projected to decline from approximately 23.83 billion RMB in 2018 to about 21.32 billion RMB by 2027 [31] - The recommended scale for ordinary screening is also expected to decrease, from 80.05 billion RMB in 2018 to 76.80 billion RMB by 2027 [43] Coverage Rate - The recommended coverage rate for hepatitis screening is expected to increase from 30% in 2018 to 80% by 2028, reflecting a significant push towards higher screening rates [52]
中国肝炎早筛行业市场规模测算逻辑模型 头豹词条报告系列
Tou Bao Yan Jiu Yuan·2025-01-08 12:05